ZA200307718B - Pharmaceutical composition based on macrolides for topical application in ophthalmology. - Google Patents
Pharmaceutical composition based on macrolides for topical application in ophthalmology. Download PDFInfo
- Publication number
- ZA200307718B ZA200307718B ZA200307718A ZA200307718A ZA200307718B ZA 200307718 B ZA200307718 B ZA 200307718B ZA 200307718 A ZA200307718 A ZA 200307718A ZA 200307718 A ZA200307718 A ZA 200307718A ZA 200307718 B ZA200307718 B ZA 200307718B
- Authority
- ZA
- South Africa
- Prior art keywords
- eye
- azithromycin
- oily vehicle
- pharmaceutical composition
- composition
- Prior art date
Links
- 239000003120 macrolide antibiotic agent Substances 0.000 title claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- 229940041033 macrolides Drugs 0.000 title description 11
- 230000000699 topical effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 56
- 229960004099 azithromycin Drugs 0.000 claims description 52
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 51
- 239000003981 vehicle Substances 0.000 claims description 38
- 239000006210 lotion Substances 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 16
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 13
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 10
- 208000001860 Eye Infections Diseases 0.000 claims description 9
- 208000011323 eye infectious disease Diseases 0.000 claims description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- -1 fatty acid triglycerides Chemical class 0.000 claims description 7
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 6
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 6
- 150000001735 carboxylic acids Chemical class 0.000 claims description 6
- 229960002446 octanoic acid Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000010685 fatty oil Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- OSKIPPQETUTOMW-YHLOVPAPSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2R,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 OSKIPPQETUTOMW-YHLOVPAPSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 38
- 229940057917 medium chain triglycerides Drugs 0.000 description 18
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 8
- 229960003276 erythromycin Drugs 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 229940126601 medicinal product Drugs 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 5
- 150000002596 lactones Chemical group 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 206010047513 Vision blurred Diseases 0.000 description 4
- 229960004926 chlorobutanol Drugs 0.000 description 4
- 229960002626 clarithromycin Drugs 0.000 description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960005224 roxithromycin Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 231100001032 irritation of the eye Toxicity 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0105114A FR2823441B1 (fr) | 2001-04-12 | 2001-04-12 | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307718B true ZA200307718B (en) | 2004-09-02 |
Family
ID=8862340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307718A ZA200307718B (en) | 2001-04-12 | 2003-10-02 | Pharmaceutical composition based on macrolides for topical application in ophthalmology. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7064109B2 (cs) |
| EP (1) | EP1377316B1 (cs) |
| JP (2) | JP4558275B2 (cs) |
| KR (1) | KR100835002B1 (cs) |
| CN (1) | CN1496270B (cs) |
| AR (1) | AR034033A1 (cs) |
| AT (1) | ATE397460T1 (cs) |
| BR (1) | BRPI0208367B8 (cs) |
| CA (1) | CA2443728C (cs) |
| CY (1) | CY1108302T1 (cs) |
| CZ (1) | CZ300213B6 (cs) |
| DE (1) | DE60226962D1 (cs) |
| DK (1) | DK1377316T3 (cs) |
| EA (1) | EA008088B1 (cs) |
| EG (1) | EG23169A (cs) |
| ES (1) | ES2307754T3 (cs) |
| FR (1) | FR2823441B1 (cs) |
| HK (1) | HK1065708A1 (cs) |
| HR (1) | HRP20030907B1 (cs) |
| HU (1) | HU230459B1 (cs) |
| MA (1) | MA27005A1 (cs) |
| MX (1) | MXPA03009349A (cs) |
| OA (1) | OA12462A (cs) |
| PA (1) | PA8543401A1 (cs) |
| PE (1) | PE20021082A1 (cs) |
| PL (1) | PL204403B1 (cs) |
| PT (1) | PT1377316E (cs) |
| SI (1) | SI1377316T1 (cs) |
| TN (1) | TNSN03091A1 (cs) |
| WO (1) | WO2002083178A1 (cs) |
| ZA (1) | ZA200307718B (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE412400T1 (de) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
| FR2884716B1 (fr) * | 2005-04-22 | 2009-08-21 | Thea Sa Lab | Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires |
| JPWO2007074904A1 (ja) * | 2005-12-28 | 2009-06-04 | わかもと製薬株式会社 | 水性医薬組成物 |
| CA2679448A1 (en) * | 2007-02-28 | 2008-09-04 | Aciex, Inc. | Methods and compositions for normalizing meibomian gland secretions |
| US20100158821A1 (en) * | 2008-12-22 | 2010-06-24 | Eastman Chemical Company | Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products |
| CN101780105B (zh) * | 2009-01-20 | 2011-09-28 | 沈阳兴齐制药有限公司 | 小牛血去蛋白提取物的滴眼液 |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| US8106111B2 (en) * | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
| EP2394636B1 (en) * | 2010-05-28 | 2014-03-19 | Novagali Pharma S.A. | Method for treating retinal conditions using an intraocular tamponade |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| US9044508B2 (en) * | 2013-03-15 | 2015-06-02 | Insite Vision Corporation | Concentrated aqueous azalide formulations |
| CA3029281A1 (en) * | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| DK3266446T3 (en) * | 2016-07-07 | 2019-02-11 | Salvat Lab Sa | Eye preparation comprising castor oil and medium chain triglyceride |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1152644A (en) * | 1966-07-01 | 1969-05-21 | Abbott Lab | Stable Solutions of Erythromycin Free Base |
| JPS6468328A (en) * | 1987-09-09 | 1989-03-14 | Suntory Ltd | Anticorneoulcerative |
| JP2563336B2 (ja) * | 1987-06-01 | 1996-12-11 | エーザイ株式会社 | 角膜透過促進点眼剤 |
| FR2746035B1 (fr) * | 1996-03-15 | 1998-06-12 | Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications | |
| DE69825128T3 (de) * | 1997-12-02 | 2010-05-06 | Pfizer Products Inc., Groton | Verwendung von azithromycin zur topischen behandlung von augeninfektionen |
| JP2000159659A (ja) * | 1998-11-30 | 2000-06-13 | Kazuo Tsubota | 眼科用人工涙液 |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
-
2001
- 2001-04-12 FR FR0105114A patent/FR2823441B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-09 PA PA20028543401A patent/PA8543401A1/es unknown
- 2002-04-10 AR ARP020101319A patent/AR034033A1/es not_active Application Discontinuation
- 2002-04-10 EG EG20020380A patent/EG23169A/xx active
- 2002-04-11 PT PT02732804T patent/PT1377316E/pt unknown
- 2002-04-11 PE PE2002000306A patent/PE20021082A1/es not_active Application Discontinuation
- 2002-04-11 SI SI200230723T patent/SI1377316T1/sl unknown
- 2002-04-11 CZ CZ20032771A patent/CZ300213B6/cs not_active IP Right Cessation
- 2002-04-11 HU HU0303864A patent/HU230459B1/hu unknown
- 2002-04-11 JP JP2002580979A patent/JP4558275B2/ja not_active Expired - Lifetime
- 2002-04-11 WO PCT/FR2002/001263 patent/WO2002083178A1/fr active IP Right Grant
- 2002-04-11 KR KR1020037012372A patent/KR100835002B1/ko active IP Right Grant
- 2002-04-11 PL PL363538A patent/PL204403B1/pl unknown
- 2002-04-11 EA EA200301108A patent/EA008088B1/ru not_active IP Right Cessation
- 2002-04-11 DE DE60226962T patent/DE60226962D1/de not_active Expired - Lifetime
- 2002-04-11 CN CN02806447XA patent/CN1496270B/zh not_active Expired - Lifetime
- 2002-04-11 CA CA2443728A patent/CA2443728C/fr not_active Expired - Lifetime
- 2002-04-11 AT AT02732804T patent/ATE397460T1/de active
- 2002-04-11 TN TNPCT/FR2002/001263A patent/TNSN03091A1/fr unknown
- 2002-04-11 ES ES02732804T patent/ES2307754T3/es not_active Expired - Lifetime
- 2002-04-11 OA OA1200300246A patent/OA12462A/fr unknown
- 2002-04-11 US US10/474,811 patent/US7064109B2/en not_active Expired - Lifetime
- 2002-04-11 EP EP02732804A patent/EP1377316B1/fr not_active Expired - Lifetime
- 2002-04-11 MX MXPA03009349A patent/MXPA03009349A/es active IP Right Grant
- 2002-04-11 BR BRPI0208367A patent/BRPI0208367B8/pt not_active IP Right Cessation
- 2002-04-11 DK DK02732804T patent/DK1377316T3/da active
-
2003
- 2003-09-26 MA MA27325A patent/MA27005A1/fr unknown
- 2003-10-02 ZA ZA200307718A patent/ZA200307718B/en unknown
- 2003-11-10 HR HR20030907A patent/HRP20030907B1/xx not_active IP Right Cessation
-
2004
- 2004-11-01 HK HK04108553.8A patent/HK1065708A1/xx not_active IP Right Cessation
-
2008
- 2008-08-28 CY CY20081100927T patent/CY1108302T1/el unknown
-
2009
- 2009-10-08 JP JP2009234250A patent/JP5170780B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5170780B2 (ja) | 眼科における局所用のマクロライド系医薬品組成物 | |
| US6960346B2 (en) | Vehicles for delivery of biologically active substances | |
| KR101786760B1 (ko) | 프로스타글란딘을 함유하는 음이온성 수중유형 에멀젼 및 그의 용도 | |
| HU204202B (en) | Process for producing new, local pharmaceutical compositions | |
| MX2007003789A (es) | Suministro ocular de formulaciones polimericas para suministro. | |
| EP0274714B1 (en) | Topical preparation containing ofloxacin | |
| SI9620048A (sl) | Sterilni očesni gelni pripravek, uporaben v obliki kapljic, in postopek za njegovo pripravo | |
| EP2394636B1 (en) | Method for treating retinal conditions using an intraocular tamponade | |
| EP4029493A1 (en) | Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof | |
| JP7080268B2 (ja) | 一酸化窒素放出プロスタミドを含有する眼科用組成物 | |
| AU661944B2 (en) | An aqueous suspension | |
| JPH05139955A (ja) | 安定な点眼剤 | |
| KR101510764B1 (ko) | 사이클로스포린 함유 안약 조성물 및 그 제조방법 | |
| KR102656260B1 (ko) | 목시플록사신을 포함하는 안과용 조성물 | |
| CA3091413A1 (en) | Triazole-containing macrolides and ophthalmic uses therefor |